Exodus Point Capital Management, LP Allogene Therapeutics, Inc. Transaction History
Exodus Point Capital Management, LP
- $14.7 Billion
- Q2 2024
A detailed history of Exodus Point Capital Management, LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 291,114 shares of ALLO stock, worth $753,985. This represents 0.0% of its overall portfolio holdings.
Number of Shares
291,114
Previous 163,023
78.57%
Holding current value
$753,985
Previous $729,000
7.0%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$48.5 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$42.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$21.2 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$19.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$17.9 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $372M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...